Basis of Presentation and Significant Accounting Policies - Summary of Significant Expense Categories Regularly Reviewed CODM (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2025	Jun. 30, 2024
Significant Accounting Policies [Line Items]
Collaboration revenue	$ 163,616		$ 3,425,271		$ 421,500	$ 3,552,109
Research and development expenses:
Total research and development expenses	3,663,103		4,566,152		8,877,179	7,704,311
General and administrative expenses:
Employee related costs	684,844		667,996		1,368,927	1,343,978
Stock-based compensation	677,926		373,918		1,373,319	641,356
Other general and administrative expenses	1,545,421		1,046,490		2,879,835	2,542,911
Total general and administrative expenses	2,908,191		2,088,404		5,622,081	4,528,245
In-process research and development						25,000
Depreciation	6,840		6,840		13,680	13,680
Other income	(319,541)		(344,445)		(689,706)	(775,534)
Net loss	(6,094,977)	$ (7,306,757)	(2,891,680)	$ (5,051,913)	(13,401,734)	(7,943,593)
Preclinical product candidates
Research and development expenses:
Total research and development expenses	2,486,265		3,721,547		6,508,641	6,216,836
Sponsored research
Research and development expenses:
Total research and development expenses	282,805		111,433		485,215	213,419
Internal research and development expenses, including stock-based compensation
Research and development expenses:
Total research and development expenses	$ 894,033		$ 733,172		$ 1,883,323	$ 1,274,056